Sacramento Telehealth Company Positions Multi-Form Compounded Semaglutide Access Through Licensed Medical Providers Ahead of ...

The arrival of GLP-1 medications like Ozempic® and Wegovy® has been nothing short of revolutionary for weight loss and diabetes management. These drugs, which include active ingredients like ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...

As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

Intro: Clinic Secret Enters the Spotlight as GLP-1 Telehealth Platforms Gain National Attention. New York City, NY, Dec. 18, ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Today, Novo Nordisk announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) ...

Novo Nordisk (NVO) stock gains as the company files for FDA approval of CagriSema, its next-gen obesity drug which causes up ...

Emil Kongshøj Larsen, Executive Vice President for International Operations at Novo Nordisk, talks to BT about India’s role ...

Learn more about what to expect if you’ve been prescribed this weight loss medication to help treat this chronic liver condition.

Explore Veru's Q4 2025 earnings, strategic shift to drug development, regulatory clarity, and new trials for obesity management.